The objectives of the study were therefore, (i) to evaluate whether aCD3 treatment in mice replicates the CD8 T-cell subset modulation seen in humans and investigate their CXCR3 expression, and (ii) to assess whether the combination of aCD3 with the CXCR3 antagonist ACT-777991 [29] enhances type 1 diabetes control in preclinical models. Here, CD8A is linked to type 1 diabetes mellitus.